Prescription drug abuse: Which data in order to evaluate and prevent;Addiction médicamenteuse : Quelles données pour évaluer et prévenir

Psychotropes (Belgium)

Volumn 19, Issue 1, 2013, Pages 65-80

  Lapeyre Mestre, Maryse ^a  

^a Faculté de Médecine Centre Hospitalo universitaire   (France)

Author keywords

Abuse; Addiction; Benzodiazepine; Drug; Evaluation; France; Misuse; Pharmacovigilance; Psychoactive drug

Indexed keywords

PSYCHOTROPIC AGENT;

ARTICLE; DRUG ABUSE; DRUG INDUSTRY; FRANCE; HEALTH PRACTITIONER; HUMAN;

EID: 84889862437     PISSN: 12452092     EISSN: 17821487     Source Type: Journal    
DOI: 10.3917/psyt.191.0065     Document Type: Article

References (51)

1. Acquaviva E., Legleye S., Auleley G. R., Deligne J., Carel D., Falissard B. B. (2009). Psychotropic medication in the French child and adolescent population: Prevalence estimation from health insurance data and national self-report survey data, BMC Psychiatry, 9, p. 72.
2. Alonso J., Angermeyer M. C., Bernert S., Bruffaerts R., Brugha T. S., Bryson H., de Girolamo G., Graaf R., Demyttenaere K., Gasquet I., Haro J. M., Katz S. J., Kessler R. C., Kovess V., Lepine J. P., Ormel J., Polidori G., Russo L. J., Vilagut G., Almansa J., Arbabzadeh-Bouchez S., Autonell J., Bernal M., Buist-Bouwman M. A., Codony M., Domingo-Salvany A., Ferrer M., Joo S. S., Martinez-Alonso M., Matschinger H., Mazzi F., Morgan Z., Morosini P., Palacin C., Romera B., Taub N., Vollebergh W. A. (2004). Psychotropic drug utilization in Europe: Results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project, Acta Psychiatr Scand Suppl, 420, p. 55-64.
3. Armand C., Thirion X., Saillard C., Lapeyre-Mestre M., Lambert H. (2004). [Neocodion misuse: Evolution between 1992 and 2002], Therapie, 59(5) 547-553.
4. Barrau K., Thirion X., Micallef J., Chuniaud-Louche C., Bellemin B., San Marco J. L. (2001). Comparison of methadone and high dosage buprenorphine users in French care centres, Addiction, 96(10) 1433-1441.
5. Baumevieille M., Haramburu F., Begaud B. (1997). Abuse of prescription medicines in southwestern France, Ann Pharmacother, 31(7-8) 847-850.
6. Baumevieille M., Miremont G., Haramburu F., Maurain C., Begaud B. (2001), [The French system of evaluation of dependence: Establishment in a legal system], Therapie, 56(1) 15-22.
7. Baumevieille M., Daveluy A., Maurain C., Begaud B., Haramburu F. (2009). Medicines submitted to narcotics regulations in France, 1992-2007, Fundam.Clin Pharmacol, 23(3) 345-349.
8. Bernard N., Bellemin B., Thirion X., Chuniaud-Louche C., Descotes J. (2002). [OPPIDUM, a tool for assessing the local misuse of psychotropic drugs], Therapie, 57(2) 198-201.
9. Billioti de Gage S., Begaud B., Bazin F., Verdoux H., Dartigues J. F., Peres K., Kurth T., Pariente A. (2012). Benzodiazepine use and risk of dementia: Prospective population based study, BMJ, 345, p. e6231.
10. Bismuth S., Leng E. L., Oustric S., Montastruc J. L., Lapeyre-Mestre M. (2011). [Which Analgesic after Dextropropoxyphene Withdrawal A Survey in a Sample of General Practitioners in Southwest of France], Therapie, 66(1) 25-28.
11. Boeuf O., Lapeyre-Mestre M. (2007). Survey of forged prescriptions to investigate risk of psychoactive medications abuse in France: Results of OSIAP survey, Drug Saf, 30(3) 265-276.
12. Bruggisser M., Bodmer M., Liechti M. E. (2011). Severe toxicity due to injected but not oral or nasal abuse of methylphenidate tablets, Swiss Medical Weekly, 141.
13. Casati A., Sedefov R., Pfeiffer-Gerschel T. (2012). Misuse of medicines in the European Union: A systematic review of the literature, Eur Addict Res, 18(5) 228-245.
14. Djezzar S., Questel F., Burin E., Dally S. (2009). Chemical submission: Results of 4-year French inquiry, Int J Legal Med, 123(3) 213-219.
15. Doazan O., Lapeyre-Mestre M., Roussin A. (2008). Tramadol abuse and dependence: A pilot study in community pharmacies, Fundamental & Clinical Pharmacology, 22, p. 83-85.
16. Dugarin J., Gatignol C. (2004). La Commission nationale des stupéfiants et des psychotropes ;, Psychotropes 10(3) 131-152.
17. Fisher J., Sanyal C., Frail D., Sketris I. (2012). The intended and unintended consequences of benzodiazepine monitoring programmes: A review of the literature, J Clin Pharm Ther, 37(1) 7-21.
18. Frauger E., Pauly V., Pradel V., Rouby F., Arditti J., Thirion X., Lapeyre Mestre M., Micallef J. (2010). Evidence of clonazepam abuse liability: Results of the tools developed by the French Centers for Evaluation and Information on Pharmacodependence (CEIP) network, Fundam Clin Pharmacol.
19. Frauger E., Djezzar S., Bongiovanini B., Spadari M., Malarde T., Nordmann S., Thirion X., Mallaret M., Lapeyre-Mestre M., Micallef J., Des Ceip-Addictovigilance L. (2011a), Signal detection of abuse in post-marketing surveillance in a specific geographical area: About methylphenidate, Fundamental & Clinical Pharmacology, 25, p. 59-60.
20. Frauger E., Pauly V., Natali F., Pradel V., Reggio P., Coudert H., Thirion X., Micallef J. (2011b). Patterns of methylphenidate use and assessment of its abuse and diversion in two French administrative areas using a proxy of deviant behaviour determined from a reimbursement database: Main trends from 2005 to 2008, CNS Drugs, 25(5) 415-424.
21. Frauger E., Spadari M., Djezzar S., Malarde T., Allaria-Lapierre V., Sciortino V., Thirion X., Micallef J. (2012). Study on intravenous use of methylphenidate and patterns on its abuse and diversion in two French administrative Areas (PACA, Corse), Fundamental & Clinical Pharmacology, 26, p. 72-73.
22. Gibaja V., Seyer D., Lambert H., Kahn J. (2011). Prescription and misuse of fentanyl: Results from a survey from the Medical Department of North East Social Security (France), over years 2007-2009, Fundamental & Clinical Pharmacology, 25, p. 75-76.
23. Glass J., Lanctot K. L., Herrmann N., Sproule B. A., Busto U. E. (2005). Sedative hypnotics in older people with insomnia: Meta-analysis of risks and benefits, BMJ, 331(7526) 1169.
24. Hernandez S. H., Nelson L. S. (2010). Prescription drug abuse: Insight into the epidemic, Clin Pharmacol Ther, 88(3) 307-317.
25. Hibell B., Guttormsson U., Ahlström S., Balakireva O., Bjarnason T., Kokkevi A., Kraus L. (2009). The 2007 ESPAD report. Substance use among students in 35 European countries, p. 1-408.
26. Jouanjus E., Leymarie F., Tubery M., Lapeyre-Mestre M. (2011). Cannabis-related hospitalizations: Unexpected serious events identified through hospital databases, Br J Clin Pharmacol, 71(5) 758-765.
27. Jouanjus E., Pourcel L., Saivin S., Molinier L., Lapeyre-Mestre M. (2012). Use of multiple sources and capture-recapture method to estimate the frequency of hospitalizations related to drug abuse, Pharmacoepidemiol Drug Saf, 21(7) 733-741.
28. Knellwolf A. L., Deligne J., Chiarotti F., Auleley G. R., Palmieri S., Boisgard C. B., Panei P., Autret-Leca E. (2008). Prevalence and patterns of methylphenidate use in French children and adolescents, Eur J Clin Pharmacol, 64(3) 311-317.
29. Kokkevi A., Fotiou A., Arapaki A., Richardson C. (2008). Prevalence, patterns, and correlates of tranquilizer and sedative use among European adolescents, J Adolesc. Health, 43(6) 584-592.
30. Kokkevi A. E., Arapaki A. A., Richardson C., Florescu S., Kuzman M., Stergar E. (2007). Further investigation of psychological and environmental correlates of substance use in adolescence in six European countries, Drug Alcohol Depend, 88(2-3) 308-312.
31. Kripke D. F., Langer R. D., Kline L. E. (2012). Hypnotics' association with mortality or cancer: A matched cohort study, BMJ Open, 2(1) e000850.
32. Lapeyre-Mestre M., Damase-Michel C., Adams P., Michaud P., Montastruc J. L. (1997). Falsified or forged medical prescriptions as an indicator of pharmacodependence: A pilot study. Community pharmacists of the Midi-Pyrenees, Eur J Clin Pharmacol, 52(1) 37-39.
33. Llau M. E., Lapeyre-Mestre M., Plas L., Damase-Michel C., Montastruc J. L. (2002). Forged medical prescriptions in a community pharmacy network in Midi-Pyrenees area: Assessment of a falsification ratio, European Journal of Clinical Pharmacology, 57(12) 911-912.
34. Micaleff J., Jolliet P., Victorri-Vigneau C., Mallaret M., Richard N., Haramburu F., Lapeyre-Mestre M. (2008). [First meeting of the French CEIP (centres d'evaluation et d'information sur la pharmacodependance). Assessment of the abuse and pharmacodependence potential during drug development], Therapie, 63(1) 55-65.
35. Micallef J., Star K., Palmaro A., Lapeyre-Mestre M. (2012). Detection and Magnitude of Methylphenidate Abuse and Misuse Using Vigibase and Correlation with Level of Use in Europe, Pharmacoepidemiology and Drug Safety, 21, p. 450-460.
36. Modelon H., Frauger E., Laurenceau D., Thirion X., Mallaret M., Micallef J. (2007). [Psychotropic drug addiction: Consumption study of specific population by the survey OPPIDUM 2004 from the CEIP network], Therapie, 62(4) 337-346.
37. Nordmann S., Frauger E., Pauly V., Orleans V., Pradel V., Mallaret M., Thirion X., Micallef J. (2012). Misuse of buprenorphine maintenance treatment since introduction of its generic forms: OPPIDUM survey, Pharmacoepidemiology and Drug Safety, 21(2) 184-190.
38. Orriols L., Philip P., Moore N., Castot A., Gadegbeku B., Delorme B., Mallaret M., Lagarde E. (2011). Benzodiazepine-like hypnotics and the associated risk of road traffic accidents, Clin Pharmacol Ther, 89(4) 595-601.
39. Pauly V., Frauger E., Rouby F., Sirere S., Monier S., Paulet C., Gibaga V., Micallef J., Thirion X. (2010). [Analysis of addictive behaviours among new prisoners in France using the OPPIDUM program], Encephale, 36(2) 122-131.
40. Peyriere H., Eiden C., Micallef J., Lapeyre-Mestre M., Faillie J. L., Blayac J. P. (2013). Slow-Release Oral Morphine Sulfate Abuse: Results of the Postmarketing Surveillance Systems for Psychoactive Prescription Drug Abuse in France. European Addiction Research, 19(5) 235-244.
41. Roussin A., Geniaux H., Doazan-D'Ouince O., Lapeyre-Mestre M. (2009). Evaluation of Misuse, Non-Medical Use and Dependence on Tramadol: A Pharmacoepidemiological Study Based on Community Pharmacies in France, Drug Safety, 32(10) 980-990.
42. Schwartz H. I. (1991). Negative clinical consequences of triplicate prescription regulation of benzodiazepines, N Y State J Med, 91(11 Suppl) 9S-12S.
43. Schwartz H. I. (1992). An empirical review of the impact of triplicate prescription of benzodiazepines, Hosp Community Psychiatry, 43(4) 382-385.
44. Thirion X., Micallef J., Guet F., Delaroziere J. C., Arditti J., Huntsman A., Sanmarco J. L., Lagier G. (1999). [Dependence on psychotropic drugs and substitution treatment: Recent trends. The OPPIDUM study of the Centers for Evaluation and Information on Drug Dependence (CEIP), October 1997], Therapie, 54(2) 243-249.
45. Thirion X., Barrau K., Micallef J., Haramburu F., Lowenstein W., Sanmarco J. L. (2000). [Maintenance treatment for opioid dependence in care centers: The OPPIDUM program of the Evaluation and Information Centers for Drug Addiction], Annales de médecine interne, 151 Suppl A, p. A10-17.
46. Thirion X., Micallef J., Barrau K., Djezzar S., Lambert H., Sanmarco J. L., Lagier G. (2001a). Recent evolution in opiate dependence in France during generalisation of maintenance treatments, Drug and Alcohol Dependence, 61(3) 281-285.
47. Thirion X., Micallef J., Barrau K., Djezzar S., Sanmarco J. L., Lagier G. (2001b). Observation of psychoactive substance consumption: Methods and results of the French OPPIDUM programme, European addiction research, 7(1) 32-36.
48. Victorri-Vigneau C., Dailly E., Veyrac G., Jolliet P. (2007). Evidence of zolpidem abuse and dependence: Results of the French Centre for Evaluation and Information on Pharmacodependence (CEIP) network survey. British Journal of Clinical Pharmacology, 64(2) 198-209.
49. Victorri-Vigneau C., Dailly E., Veyrac G., Jolliet P. (2007). Evidence of zolpidem abuse and dependence: Results of the French Centre for Evaluation and Information on Pharmacodependence (CEIP) network survey. Br J Clin Pharmacol, 64(2) 198-209.
50. Wagner A. K., Ross-Degnan D., Gurwitz J. H., Zhang F., Gilden D. B., Cosler L., Soumerai S. B. (2007). Effect of New York State regulatory action on benzodiazepine prescribing and hip fracture rates, Ann Intern Med, 146(2) 96-103.
51. Weintraub M., Singh S., Byrne L., Maharaj K., Guttmacher L. (1991). Consequences of the 1989 New York State triplicate benzodiazepine prescription regulations 3, JAMA, 266(17) 2392-2397.